Status: affected by circulating vaccine-derived poliovirus type 2 (cVDPV2)
Egypt is affected by cVDPV2, linked to an outbreak originating in Sudan. GPEI partners, including through our regional and country offices, are continuing to assist Egyptian health authorities in conducting a complete investigation, including to ascertain more clearly the origin/source of the isolated virus, and assess potential risk of spread within the country as well as internationally.
Polio this week in Egypt
- No cVDPV2 positive environmental sample was reported this week. There are 11 positive samples reported in 2021.
- The region’s first nOPV2 campaign was completed in Egypt on 19 December. Administrative coverage data from the campaign indicates a high-quality round with 99% coverage.
- Intra-campaign monitoring focused on pre-identified high-risk areas and were found to be well covered.
- Lot Quality Assurance Survey (LQAS) conducted following the round indicate that 83% of the districts surveyed passed with higher than 90% coverage. The Ministry of Health, supported by WHO, is conducting additional follow up assessments in targeted areas that were found to be underperforming.
- Read our Egypt country page for more information.
International Health Regulations
Countries affected by poliovirus circulation are subject to temporary recommendations issued by the Emergency Committee of the International Health Regulations on Poliovirus, under the auspices of the Public Health Emergency of International Concern. The latest report by the Committee is as of November 2021.
WHO’s International Travel and Health recommends that all travellers to polio-affected areas be fully vaccinated against polio. Residents (and visitors for more than 4 weeks) from infected areas should receive an additional dose of OPV or inactivated polio vaccine (IPV) within 4 weeks to 12 months of travel.